184 related articles for article (PubMed ID: 23207012)
1. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Matsuura K; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Nakai T; Hirata K
BMC Cancer; 2012 Dec; 12():568. PubMed ID: 23207012
[TBL] [Abstract][Full Text] [Related]
2. Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Hirata K
Osaka City Med J; 2012 Jun; 58(1):25-34. PubMed ID: 23094511
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Takimoto T; Kijima T; Otani Y; Nonen S; Namba Y; Mori M; Yokota S; Minami S; Komuta K; Uchida J; Imamura F; Furukawa M; Tsuruta N; Fujio Y; Azuma J; Tachibana I; Kumanogoh A
Clin Lung Cancer; 2013 Sep; 14(5):502-7. PubMed ID: 23664723
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
6. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
7. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Kobayashi H; Sato K; Niioka T; Takeda M; Okuda Y; Asano M; Ito H; Miura M
Med Oncol; 2016 Jun; 33(6):57. PubMed ID: 27154635
[TBL] [Abstract][Full Text] [Related]
8. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
10. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
[TBL] [Abstract][Full Text] [Related]
11. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Yoshida T; Yamada K; Azuma K; Kawahara A; Abe H; Hattori S; Yamashita F; Zaizen Y; Kage M; Hoshino T
Med Oncol; 2013 Mar; 30(1):349. PubMed ID: 23263831
[TBL] [Abstract][Full Text] [Related]
12. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
[TBL] [Abstract][Full Text] [Related]
13. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Perez-Soler R
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
[TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Kaira K; Naito T; Takahashi T; Ayabe E; Shimoyama R; Kaira R; Ono A; Igawa S; Shukuya T; Murakami H; Tsuya A; Nakamura Y; Endo M; Yamamoto N
Lung Cancer; 2010 Apr; 68(1):99-104. PubMed ID: 19540616
[TBL] [Abstract][Full Text] [Related]
15. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
[TBL] [Abstract][Full Text] [Related]
16. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
18. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
20. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
